UCB Full Year Report 2018: 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's

ACTUAL VARIANCE EUR million 2018 2017 ACTUAL RATES CER Revenue 4 632 4 530 2% 5% Net sales 4 412 4 182 5% 8% --- Royalty income and fees 92 108 -15% -11% --- Other revenue 128 240 -47% -46% Gross Profit 3 434 3 330 3% 6% Marketing and selling expenses - 964 - 940 3% 6% --- Research and development expenses -1 161 -1 057 10% 11% --- General and administrative expenses - 180 - 192 -6% -5% --- Other operating income/expenses (-) - 24 - 11 >100% >100% Recurring EBIT (rEBIT) 1 105 1 130 -2% 1% Non recurring income/expenses (-) 4 - 43 >-100% >-100% EBIT (operating profit) 1 109 1 087 2% 5% Net financial expenses - 93 - 99 -6% -5% Profit before income taxes 1 015 988 3% 6% Income tax expenses - 200 - 218 -8% -5% Profit from continuing operations 815 770 6% 9% Profit/loss (-) from discontinued operations 8 1 >100% >100% Profit 823 771 7% 10% Attributable to UCB shareholders 800 753 6% 10% --- Attributable to non-controlling interests 23 18 26% 32% Recurring EBITDA 1 398 1 375 2% 5% Capital expenditure (including intangible assets) 341 209 63% --- Net financial debt 237 525 -55% --- Operating cash flow from continuing operations 1 098 896 23% Weighted average number of shares - non diluted (million) 188 188 0% EPS (EUR per weighted average number of shares - non diluted) 4.24 4.00 6% 6% Core EPS (EUR per weighted average number of shares - non diluted) 4.78 4.82 -1% 3%

Due to rounding, some financial data may not add up in the tables.

"The statutory auditor has issued an unqualified report with no emphasis of matter paragraph dated 27 February 2019 on the company's consolidated accounts as of and for the year ended 31 December 2018, and has confirmed that the accounting data reported in the accompanying press release is consistent, in all material respects, with the accounts from which it has been derived."

UCB will host a conference call/video webcast at 08.00 (EDT) / 13.00 (BST) 14.00 (CEST).

Details are available onhttp://www.ucb.com/investors/UCB-financials/Full-year-financ... [http://www.ucb.com/investors/UCB-financials/Full-year-financ...].

About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With around 7 500 people in approximately 40 countries, the company generated revenue of EUR 4.6 billion in 2018. UCB is listed on Euronext Brussels . Follow us on Twitter: @UCB_news

Forward looking statementsThis press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Check out our IR App on https://itunes.apple.com/us/app/ucb-ir-app/id1135906235?ls=1... [https://itunes.apple.com/us/app/ucb-ir-app/id1135906235?ls=1...] and https://play.google.com/store/apps/detai... [https://play.google.com/store/apps/detai...]

CONTACT: Investor Relations, Antje Witte, Investor Relations, UCB,T+32.2.559.9414, antje.witte@ucb.com, Isabelle Ghellynck, InvestorRelations, UCB, T+32.2.559.9588, isabelle.ghellynck@ucb.com, GlobalCommunications, France Nivelle, Global Communications, UCB, T+32.2.559.9178, france.nivelle@ucb.com, Laurent Schots, Media Relations, UCB, T+32.2.559.9264, laurent.schots@ucb.com